sur POXEL (EPA:POXEL)
Poxel Reports Outcomes of General Meeting and Looks Ahead
Poxel SA, a biopharmaceutical company focusing on treatments for chronic diseases, has announced the results of its Combined General Meeting held on December 11, 2025. The meeting took place at the Mercure Lyon Centre Château Perrache Hotel in Lyon, France. The event was attended by shareholders holding 19,381,917 voting rights, representing a quorum of 36.123%.
A key takeaway from the meeting was the adoption of resolutions, viewed positively by the Board of Directors. The company extends its gratitude to shareholders for their support. Details of the voting results and other presentations are accessible on Poxel's website.
Looking forward, Poxel anticipates the validation of a recovery plan by the Lyon Economic Court in January 2026, crucial for the company's future after current legal proceedings.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de POXEL